Compared with the patients taking enalapril, the patients randomized to ARNI experienced a significantly greater decrease in NT-proBNP level during the therapy, along with a significantly reduced risk of composite adverse clinical outcomes including death, rehospitalization for HF, implantation of a left ventricular device, and inclusion on a heart transplant eligibility list [39]. This evidence concerns the gene NPPB and hydrops fetalis.